Coal Tar Prepared
Recommended DermatologyUnrestrictedNot applicable line
Treatment of psoriasis. Scytera® Foam provides coal tar in a foam formulation designed to improve patient adherence through easier application and cosmetic acceptability.
2
Submissions
1 resub
2005–14
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Nov 2014 Recommended foam aerosol, 2% (20 mg/g), 100 g, Scytera® Foam Dr Reddy’s Laboratories Australia Pty Ltd New Listing (Minor submission) Psoriasis Unrestricted benefit listing.
Access path
- Jul 2005Recommended
vs extemporaneous coal tar preparations
- Nov 2014Recommended
Comparator changed: extemporaneous coal tar preparations → Exorex™ (coal tar prepared 1%…
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
6.1 The PBAC recommended the listing of coal tar prepared 2% foam as an unrestricted benefit for the treatment of psoriasis based on the equi-effectiveness of 1 g of Scytera® to 1 mL of Exorex™.PSD · Nov 2014
6.2 The PBAC recommended that the Safety Net 20 Day Rule should apply for Scytera®.PSD · Nov 2014
Clinical claim
5.7 The submission claimed that Scytera® foam will provide patients with the clinical benefits of prepared coal tar (in a demonstrated effective and tolerable strength) in a patient-preferred formulation (foam) which is likely to improve patient adherence to therapy and resultant effectiveness. PricingPSD · Nov 2014
5.8 Scytera® (prepared coal tar 2% w/w) foam may be considered therapeutically equivalent to the comparator Exorex™ (prepared coal tar 1% w/w) lotion.PSD · Nov 2014
Cost-effectiveness
Not modelled; this is a minor submission (formulation change/cost-minimisation). No economic evaluation was conducted.
The PBAC recommended the listing of coal tar prepared 2% foam as an unrestricted benefit for the treatment of psoriasis based on the equi-effectiveness of 1 g of Scytera® to 1 mL of Exorex™. PBAC · 2014
Surrogate endpointCost-effectiveness accepted ×2
Decision context
PopulationPatients with psoriasis requiring topical coal tar therapy.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2014 | Recommended | Exorex™ (coal tar prepared 1% lotion) | — | Single-arm · Other |
| Jul 2005 | Recommended | extemporaneous coal tar preparations | — | RCT · Psoriasis severity (Total Sign Score / Psoriasis Severity Index) |
Similar precedents
Regulatory · TGA
Label equal than PBS population — Both indicate treatment of psoriasis patients; PBAC adds formulation detail and adherence rationale but does not restrict the patient population.